SYNB:NYE-Putnam Biorevolution ETF (USD)

ETF | Others |

Last Closing

USD 29.943

Change

+0.26 (+0.89)%

Market Cap

USD 5.36M

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SOJE Southern Company (The) Series ..

-0.10 (-0.52%)

USD 65.72B
JEPI JPMorgan Equity Premium Income..

+0.19 (+0.33%)

USD 37.61B
DFAC Dimensional U.S. Core Equity 2..

+0.16 (+0.46%)

USD 33.40B
SGOV iShares® 0-3 Month Treasury B..

+0.02 (+0.02%)

USD 28.50B
JPST JPMorgan Ultra-Short Income ET..

N/A

USD 28.13B
DTB DTE Energy Company 2020 Series

-0.03 (-0.16%)

USD 26.58B
GBTC Grayscale Bitcoin Trust (BTC)

-2.76 (-3.61%)

USD 21.47B
JAAA Janus Detroit Street Trust - J..

-0.22 (-0.43%)

USD 16.06B
AVUV Avantis® U.S. Small Cap Value..

-0.02 (-0.02%)

USD 15.95B
DFUS Dimensional U.S. Equity ETF

+0.35 (+0.54%)

USD 13.15B

ETFs Containing SYNB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.89% 43% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.89% 26% F 35% F
Trailing 12 Months  
Capital Gain 3.53% 44% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.53% 28% F 37% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.76% 75% C 57% F
Dividend Return 6.76% 71% C- 49% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.01% 63% D 84% B
Risk Adjusted Return 84.38% 87% B+ 90% A-
Market Capitalization 5.36M 10% F 4% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.